Soluble VEGF Receptor-2 May Be a Predictive Marker of Anti-Angiogenic Therapy With Clinically Available Safe Agents

Oncology Letters - Greece
doi 10.3892/ol.2010.196
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Imatinib May Be ABL to Improve Anti-Angiogenic Therapy

Molecular and Cellular Oncology
Cancer ResearchMolecular Medicine
2015English

Anti-Angiogenic Alternatives to VEGF Blockade

Clinical and Experimental Metastasis
MedicineCancer ResearchOncology
2015English

Serum Soluble Interleukin-2 Receptor Level Is More Sensitive Than Angiotensin-Converting Enzyme or Lysozyme for Diagnosis of Sarcoidosis and May Be a Marker of Multiple Organ Involvement

Journal of Dermatology
DermatologyMedicine
2017English

Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-Vegf Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2003English

Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy

Pharmaceutics
Pharmaceutical Science
2019English

Anti-Tumor Innate Immunity Activated by Intermittent Metronomic Cyclophosphamide Treatment of 9L Brain Tumor Xenografts Is Preserved by Anti-Angiogenic Drugs That Spare VEGF Receptor 2

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2014English

Bufalin Enhances Anti-Angiogenic Effect of Sorafenib via AKT/VEGF Signaling

International Journal of Oncology
Cancer ResearchOncology
2016English

Anterior Gradient�2 as a Supervisory Marker for Tumor Vessel Normalization Induced by Anti‑angiogenic Treatment

Oncology Letters
Cancer ResearchOncology
2018English

Routine Measurement of Fibrinogen Concentration. Fibrinogen May Be Just a Marker.

BMJ
1993English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy